title: BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells.
abstract: Bone marrow stromal cell antigen 2 (BST-2) is a type II transmembrane protein that is known to be a therapeutic target in several types of cancer. However, despite its clinical importance, the roles of BST-2 expression have remained elusive. Here, we found that BST-2 expression is up-regulated in tamoxifen-resistant MCF-7 human breast cancer (TRM-7) cells, resulting in enhanced invasiveness and migration. Matrigel and wound healing assays also showed that overexpression of BST-2 increased invasion and migration in MCF-7 cells, whereas invasion and migration were decreased by the silencing of BST-2 in TRM-7 cells. In addition, B16F10 cells expressing BST-2 showed increased metastatic melanoma nodule growth in a lung metastasis mouse model. Furthermore, BST-2 expression and promoter activity were regulated by activated signal transducer and activator of transcription 3 (STAT3). Taken together, our results indicate that BST-2 is an important factor in the invasiveness and motility of tamoxifen-resistant breast cancer cells, and that its expression and activity are regulated by activated STAT3. Therefore, regulation of BST-2 is a potential therapeutic target for tamoxifen-resistant breast cancer.
authors.affiliation: Department of Pharmacology and Biomedical Science, Seoul National University College of Medicine, Seoul 110-799, Republic of Korea.
authors.forename: Eun Hee
authors.initials: EH
authors.lastname: Yi
authors.forename: Hyouna
authors.initials: H
authors.lastname: Yoo
authors.forename: Kum Hee
authors.initials: KH
authors.lastname: Noh
authors.forename: Songhee
authors.initials: S
authors.lastname: Han
authors.forename: Haeri
authors.initials: H
authors.lastname: Lee
authors.forename: Jin-Ku
authors.initials: JK
authors.lastname: Lee
authors.forename: Cheolhee
authors.initials: C
authors.lastname: Won
authors.forename: Byung-Hak
authors.initials: BH
authors.lastname: Kim
authors.forename: Myoung-Hwan
authors.initials: MH
authors.lastname: Kim
authors.forename: Chung-Hyun
authors.initials: CH
authors.lastname: Cho
authors.forename: Sang-kyu
authors.initials: SK
authors.lastname: Ye
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary*; D008562:Membrane Glycoproteins / Q000378:metabolism*; D051379:Mice; D009361:Neoplasm Invasiveness / Q000473:pathology / Q000503:physiopathology; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome; D000074010:Bone Marrow Stromal Antigen 2
chemical_list: D015703:Antigens, CD; D018931:Antineoplastic Agents, Hormonal; D008562:Membrane Glycoproteins; D013629:Tamoxifen; C513868:BST2 protein, mouse; D000074010:Bone Marrow Stromal Antigen 2